Abbvie Inc. vs Jazz Pharmaceuticals, Inc.
ABBV vs JAZZ — side-by-side comparison from reported financials. ABBV leads 4, JAZZ leads 6 of 10 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Jazz Pharmaceuticals, Inc.
JAZZ · Healthcare
$218.42-1.81%Mixed
| Metric | ABBV | JAZZ |
|---|---|---|
| Price | $276.43 | $218.42 |
| Market cap | $488B | $14.2B |
| Revenue (TTM) | $64.4B | $4.60B |
| Revenue growth | +1.8% | +5.3% |
| Net margin | 9.8% | 20.4% |
| Free cash flow | $18.2B | $1.59B |
| Net cash (debt) | ($56.2B) | ($2.94B) |
| 1-year price return | +19.8% | +58.1% |
| P/E | 77.4 | 15.1 |
| P/E vs own history (cheap-side %) | 23% | 90% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 21% |
| Altman Z-score | 2.33 | 2.13 |
| CV checks passed | 9 of 11 | 9 of 11 |
| Employees | 57,000 | 2,890 |
Full résumé-style profiles: ABBV CV · JAZZ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.